Comparison of sulindac and aspirin in rheumatoid arthritis.
Thirty-one out-patients with rheumatoid arthritis took part in a 10 week double-blind comparison of sulindac (cis-5-fluoro-2-methyl-1-[p-(methylsulphinyl)-benzylidene]-indene-3-acetic acid) 200 mg twice daily and aspirin 3.6 g daily, with a 2-week placebo control period. Both drugs were superior to placebo. The incidence of side-effects was approximately the same on the two drugs, but there was a higher drop-out rate due to side-effects on aspirin.